Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterogeneity of Diabetes: Multi-Omics and Targeted Prevention
NCT06682351Phase 4Not yet recruiting
- Sponsor
- Stanford University
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of metformin in prediabetes and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Stanford University. Primary endpoint: Change in HbA1c at Month 18. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
metformin
03
Conditions
prediabetestype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06682351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682351.